Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Akt/mTOR mediated induction of bystander effect signaling in a nucleus independent manner in irradiated human lung adenocarcinoma epithelial cells.

Li L, Wang L, Prise KM, Yu KN, Chen G, Chen L, Mei Y, Han W.

Oncotarget. 2017 Mar 14;8(11):18010-18020. doi: 10.18632/oncotarget.14931.

2.

Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.

Sacco AG, Worden FP.

Onco Targets Ther. 2016 Apr 4;9:1927-43. doi: 10.2147/OTT.S93720. eCollection 2016. Review.

3.

Cross talk of tyrosine kinases with the DNA damage signaling pathways.

Mahajan K, Mahajan NP.

Nucleic Acids Res. 2015 Dec 15;43(22):10588-601. doi: 10.1093/nar/gkv1166. Epub 2015 Nov 5. Review.

4.

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR; Brain Tumor Trials Collaborative.

J Neurooncol. 2016 Jan;126(1):185-92.

5.

The Frog Skin-Derived Antimicrobial Peptide Esculentin-1a(1-21)NH2 Promotes the Migration of Human HaCaT Keratinocytes in an EGF Receptor-Dependent Manner: A Novel Promoter of Human Skin Wound Healing?

Di Grazia A, Cappiello F, Imanishi A, Mastrofrancesco A, Picardo M, Paus R, Mangoni ML.

PLoS One. 2015 Jun 12;10(6):e0128663. doi: 10.1371/journal.pone.0128663. eCollection 2015.

6.

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Schanzer JM, Wartha K, Croasdale R, Moser S, Künkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, Stracke J, Lau W, Ries S, Brinkmann U, Klein C, Umana P.

J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19.

7.

Molecular interactions of ErbB1 (EGFR) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance.

Petrás M, Lajtos T, Friedländer E, Klekner A, Pintye E, Feuerstein BG, Szöllosi J, Vereb G.

Neuro Oncol. 2013 Aug;15(8):1027-40. doi: 10.1093/neuonc/not046. Epub 2013 Apr 17.

8.

ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation.

Kambach DM, Sodi VL, Lelkes PI, Azizkhan-Clifford J, Reginato MJ.

Oncogene. 2014 Jan 30;33(5):589-98. doi: 10.1038/onc.2012.629. Epub 2013 Jan 14.

9.

IL-1beta signals through the EGF receptor and activates Egr-1 through MMP-ADAM.

Sanchez-Guerrero E, Chen E, Kockx M, An SW, Chong BH, Khachigian LM.

PLoS One. 2012;7(7):e39811. doi: 10.1371/journal.pone.0039811. Epub 2012 Jul 6. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/a0bc2cbb-0390-4476-833d-30ce4f829794.

10.

Regulation of Caenorhabditis elegans p53/CEP-1-dependent germ cell apoptosis by Ras/MAPK signaling.

Rutkowski R, Dickinson R, Stewart G, Craig A, Schimpl M, Keyse SM, Gartner A.

PLoS Genet. 2011 Aug;7(8):e1002238. doi: 10.1371/journal.pgen.1002238. Epub 2011 Aug 25.

11.

Diverse injurious stimuli reduce protein tyrosine phosphatase-μ expression and enhance epidermal growth factor receptor signaling in human airway epithelia.

Hyun SW, Anglin IE, Liu A, Yang S, Sorkin JD, Lillehoj E, Tonks NK, Passaniti A, Goldblum SE.

Exp Lung Res. 2011 Aug;37(6):327-43. doi: 10.3109/01902148.2011.566673. Epub 2011 Jun 7.

12.

Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells.

Li HF, Kim JS, Waldman T.

Radiat Oncol. 2009 Oct 14;4:43. doi: 10.1186/1748-717X-4-43.

13.

Molecular targets for tumor radiosensitization.

Tofilon PJ, Camphausen K.

Chem Rev. 2009 Jul;109(7):2974-88. doi: 10.1021/cr800504x. Review. No abstract available.

14.

The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Liu A, Mosher DF, Murphy-Ullrich JE, Goldblum SE.

Microvasc Res. 2009 Jan;77(1):13-20. doi: 10.1016/j.mvr.2008.08.008. Epub 2008 Oct 1. Review.

15.

Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.

Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE.

J Thorac Oncol. 2008 Sep;3(9):1003-11. doi: 10.1097/JTO.0b013e31818396a4.

16.

Molecular targeted therapies for pancreatic cancer.

Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM.

Am J Surg. 2008 Sep;196(3):430-41. doi: 10.1016/j.amjsurg.2008.04.009. Review.

17.

Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

Thariat J, Milas L, Ang KK.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):974-84. Review. No abstract available.

18.

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.

Combs SE, Heeger S, Haselmann R, Edler L, Debus J, Schulz-Ertner D.

BMC Cancer. 2006 May 18;6:133.

19.

Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, Didinger B, Buechler P, Heeger S, Herfarth KK, Abdollahi A, Buchler MW, Debus J.

BMC Cancer. 2005 Oct 11;5:131.

20.

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization.

Gee JM, Nicholson RI.

Breast Cancer Res. 2003;5(3):126-9. Epub 2003 Feb 20. Review.

Supplemental Content

Support Center